目的 觀察參松養(yǎng)心膠囊聯(lián)合華法林治療心房顫動的臨床療效。方法 選取2015年1月-2015年12月柞水縣人民醫(yī)院心房顫動患者106例，隨機分為治療組和對照組，每組各53例。對照組口服華法林鈉片，初始劑量1.5 mg/d，3 d后，根據(jù)國際標準化比值（INR）檢測結果調整華法林用量，確保INR處于2.0~3.0；治療組在對照組基礎上口服參松養(yǎng)心膠囊，3粒/次，3次/d。兩組患者均治療12周。觀察兩組的臨床療效，比較兩組房顫發(fā)作、心率、INR和高敏C反應蛋白（hs-CRP）的變化。結果 治療后，對照組和治療組的總有效率分別為69.81%、88.68%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組房顫發(fā)作持續(xù)時間和發(fā)作頻率均顯著下降，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標的下降程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組靜息心率和運動心率均顯著下降，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標的下降程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療4周后，兩組INR顯著上升，而hs-CRP水平顯著下降，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標的下降程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 參松養(yǎng)心膠囊聯(lián)合華法林治療心房顫動具有較好的臨床療效，可明顯改善臨床癥狀，降低hs-CRP的表達，具有一定的臨床應用推廣價值。

Objective To observe the clinical effect of Shensong Yangxin Capsules combined with warfarin in treatement of atrial fibrillation. Methods Patients (106 cases) with atrial fibrillation in Zhashui County People's Hospital from January 2015 to December 2015 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were po administered with Warfarin Sodium Tablets, 1.5 mg/d, and according to the INR results to adjust the dosage of warfarin after 3 d, ensure that the INR is 2.0-3.0. Patients in the treatment group were po administered with Shensong Yangxin Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and the changes of atrial fibrillation attack, heart rate, INR, and hs-CRP in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 69.81% and 88.68%, respectively, and there was difference between two groups (P<0.05). After treatment, the duration and frequency of atrial fibrillation attack in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, resting heart rate and exercise heart rate in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment for 4 weeks, the INR in two groups were significantly increased, but the hs-CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shensong Yangxin Capsules combined with warfarin has clinical curative effect in treatement of atrial fibrillation, and can significantly improve clinical symptoms, decrease hs-CRP level, which has a certain clinical application value.